Unknown

Dataset Information

0

Src family kinases inhibition by dasatinib blocks initial and subsequent platelet deposition on collagen under flow, but lacks efficacy with thrombin generation.


ABSTRACT: Kinase inhibitors can pose bleeding risks as platelet signaling evolves during clotting. Using microfluidics (200 s-1 wall shear rate) to perfuse Factor XIIa-inhibited or thrombin-inhibited whole blood (WB) over collagen ± tissue factor (TF), we explored the potency of the Src family kinase (SFK) inhibitor dasatinib or the spleen tyrosine kinase (Syk) inhibitor GS-9973 present at clot initiation or added after 90 s (via rapid switch to inhibitor-pretreated WB). When initially present, dasatinib potently inhibited platelet deposition on collagen (no TF). Furthermore, dasatinib immediately inhibited subsequent platelet deposition when introduced 90 s after clot initiation. However, when thrombin was generated, dasatinib was markedly less potent against platelet deposition on collagen/TF (but blocked fibrin deposition) and had no effect when added 90 s after clot initiation. Similarly, dasatinib added at 90 s had no effect on clotting on collagen/TF when fibrin was also blocked with Gly-Pro-Arg-Pro, indicating that strong thrombin-induced signaling (but not fibrin-induced signaling) can bypass the SFK inhibition at later times. The Syk inhibitor GS-9973 was less potent than dasatinib when present initially, but inhibited clot growth when added at 90 s, even in the presence of thrombin (±fibrin). Interestingly, the active form (R-406) of fostamatinib inhibits platelet function in only 2 0f 5 healthy blood samples. SFK-inhibitors may have reduced antithrombotic activity and reduced bleeding risks in settings of high TF and local thrombin generation. For oncology patients, SFK-inhibitors like dasatinib may have reduced antithrombotic activity and reduced bleeding risk in settings of local thrombin generation.

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC7306827 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Src family kinases inhibition by dasatinib blocks initial and subsequent platelet deposition on collagen under flow, but lacks efficacy with thrombin generation.

Zhang Yiyuan Y   Diamond Scott L SL  

Thrombosis research 20200513


Kinase inhibitors can pose bleeding risks as platelet signaling evolves during clotting. Using microfluidics (200 s<sup>-1</sup> wall shear rate) to perfuse Factor XIIa-inhibited or thrombin-inhibited whole blood (WB) over collagen ± tissue factor (TF), we explored the potency of the Src family kinase (SFK) inhibitor dasatinib or the spleen tyrosine kinase (Syk) inhibitor GS-9973 present at clot initiation or added after 90 s (via rapid switch to inhibitor-pretreated WB). When initially present,  ...[more]

Similar Datasets

| S-EPMC3931551 | biostudies-literature
| S-EPMC2880659 | biostudies-literature
| S-EPMC3778302 | biostudies-literature
| S-EPMC5531336 | biostudies-literature
| S-EPMC2990469 | biostudies-literature
| S-EPMC10160240 | biostudies-literature
| S-EPMC8887959 | biostudies-literature
| S-EPMC4130483 | biostudies-literature
| S-EPMC4679708 | biostudies-literature
| S-EPMC10341166 | biostudies-literature